Evaluating pharmaceuticals for health policy and reimbursement
Our rough guess is there are 67,000 words in this book.
At a pace averaging 250 words per minute, this book will take 4 hours and 28 minutes to read. With a half hour per day, this will take 9 days to read.
How long will it take you?
This book will take an estimated to read at a reading speed averaging words per minute. With 30 minutes per day, this will take to read.
Enter your reading speedYou can take one of our WPM reading speed tests to find your reading speed.
Create a free account to track your reading progress, build your reading list, and set reading goals.
We earn a commission on purchases
Author
Contributions
- Freemantle, Nick. - Contributor
- Hill, Suzanne. - Contributor
Publication
2004 - BMJ Books/Blackwell Pub., Malden, Mass, Massachusetts
Language
English
Word Count
67,000 words, Guess
Page Count
268 pages
Identifiers
- Open LibraryOL19292641M
- ISBN-100727917846
- OCLC Control Number55633936
- Library of Congress Control Number2004013561
- Goodreads1576333
Classifications
- DDC362.17/82
- LCCRA401.A1 E94 2004
Description
"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable" So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders. Chapters include Development of marketing authorisation procedures for pharmaceuticals Interpreting clinical evidence International pharmaceutical policy: health creation or wealth creation? Development of fourth hurdle policies around the world Economic modelling in drug reimbursement Priority setting in health care: matching decision criteria with policy objectives Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis Relationship between stakeholders: managing the war of words Medicine and the media: good information or misleading hype?; How to promote quality use of cost-effective medicines Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable Pricing of pharmaceuticals Evaluating pharmaceuticals for health policy in low and middle income country settings. Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.
Subjects
Other Editions
- Evaluating pharmaceuticals for health policy and reimbursement
Reader Reviews
No reviews yet for this book.
Be the first to share your thoughts!